Dow Up0.76% Nasdaq Up0.69%

Alexion Pharmaceuticals, Inc. (ALXN)

-NasdaqGS
190.29 Up 4.37(2.35%) Oct 24, 3:59PM EDT
|After Hours : 190.29 0.00 (0.00%) Oct 24, 4:57PM EDT
ProfileGet Profile for:
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
United States - Map
Phone: 203-272-2596
Fax: 203-271-8198
Website: http://www.alexionpharm.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:1,774

Business Summary 

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Alexion Pharmaceuticals, Inc.

Corporate Governance 
Alexion Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Oct 1, 2014 is 6. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 8; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Leonard Bell M.D., 56
Co-Founder, Chairman and Chief Exec. Officer
3.62M21.84M
Dr. Stephen P. Squinto Ph.D., 58
Co-Founder, Chief Global Operations Officer and Exec. VP
1.13M12.24M
Dr. Joseph A. Madri Ph.D., M.D., 67
Co-Founder
85.00KN/A
Mr. Vikas Sinha M.B.A., C.A., CPA, 51
Chief Financial Officer and Exec. VP
1.31M16.10M
Mr. David L. Hallal , 48
Chief Operating Officer and Director
1.38M16.58M
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders